dr. caffo discusses enzalutamide/docetaxel combination in frontline mcrpc
Published 5 years ago • 156 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
4:50
interview with dr. caffo
-
0:48
dr. kantoff on evolving role of docetaxel in prostate cancer treatment
-
3:44
updates from the cheiron study: docetaxel plus enzalutamide for mcrpc
-
2:31
dr. tagawa on abiraterone and docetaxel in mcrpc
-
1:57
enzalutamide after docetaxel for mcrpc: evaluation by the italian named patient program
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
5:37
oral hormonal agents for metastatc castration-resistant prostate cancer
-
3:55
optimal treatment approaches for mcrpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
8:09
treating mcrpc with newer hormonal agents
-
6:16
evolution of treatment for metastatic castration-resistant prostate cancer
-
1:07
dr. szmulewitz on optimal use of radium-223 in mcrpc
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
3:12
cabazitaxel (jevtana) for progressive metastatic prostate cancer after taxotere
-
4:17
cheiron study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patie...
-
1:10
dr. daniel petrylak discusses chemotherapy in prostate cancer